Compare LIND & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | CDNA |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.2M | 712.2M |
| IPO Year | N/A | 2014 |
| Metric | LIND | CDNA |
|---|---|---|
| Price | $11.92 | $17.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $17.00 | ★ $26.00 |
| AVG Volume (30 Days) | 350.3K | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | ★ $736,447,000.00 | $357,998,000.00 |
| Revenue This Year | $17.93 | $12.73 |
| Revenue Next Year | $9.44 | $11.90 |
| P/E Ratio | ★ N/A | $14.71 |
| Revenue Growth | ★ 18.50 | 14.46 |
| 52 Week Low | $7.45 | $10.96 |
| 52 Week High | $15.06 | $26.37 |
| Indicator | LIND | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 64.19 |
| Support Level | $11.45 | $17.50 |
| Resistance Level | $12.19 | $18.25 |
| Average True Range (ATR) | 0.39 | 0.76 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 40.19 | 82.90 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.